A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas
Crossref DOI link: https://doi.org/10.1007/s11060-017-2447-3
Published Online: 2017-04-22
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Goutagny, Stéphane
Giovannini, Marco
Kalamarides, Michel
Funding for this research was provided by:
Novartis Pharma
License valid from 2017-04-22